Lakefront Biotherapeutics (LKFT) Equity Income (2023 - 2024)
Lakefront Biotherapeutics (LKFT) posted quarterly Equity Income of $98.0 million for Q1 2024, up 293.48% year-over-year from $24.9 million in Q2 2023, and up 293.48% quarter-over-quarter from $24.9 million in Q1 2023.
Lakefront Biotherapeutics (LKFT) Equity Income (2023 - 2024) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Equity Income for 2 consecutive years, with $98.0 million the latest figure, recorded in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 98.01 Mn |
| Mar 31, 2023 | 24.91 Mn |